Vimarsana
Biggest News Aggregation in the World

Page 22 - Compugen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compugen Ltd Today - Breaking & Trending Today

Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023 - Vimarsana News

Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023

HOLON, Israel, Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. , a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will... | February 13, 2023

Compugen to Present at the SVB Securities Global Biopharma Conference - Vimarsana News

Compugen to Present at the SVB Securities Global Biopharma Conference

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...

12 Best One Dollar Stocks to Buy According To Hedge Funds - Vimarsana News

12 Best One Dollar Stocks to Buy According To Hedge Funds

In this article, we discuss 12 best one dollar stocks to buy according to hedge funds.

Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview - Vimarsana News

Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer - Vimarsana News

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavily pretreated patient population, resulted in encouraging durable confirmed partial...